

## Singapore-based startup Mesh Bio addresses chronic metabolic diseases within Asia

01 July 2022 | News

**MultiOmic Health and Mesh Bio partner to use AI to develop precision medicines and diagnostics for chronic metabolic disease**



London-based MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup in Singapore, have announced their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.

The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.

Mesh will collaborate with its network of healthcare provider customers to recruit patients for the study. MultiOmic will generate genomic, proteomic, metabolomic and potentially other omics data from anonymized body fluid samples. These will be combined with anonymized data from clinical and diagnostic tests for both companies to build a rich multi-omics dataset and derive AI-based computational biology models.

The study will enable MultiOmic and Mesh to progress their respective R&D programs to develop precision therapeutic and diagnostic products that will transform the lives of patients with metabolic syndrome-related conditions. They will also jointly conduct collaborative projects to enhance patient stratification for other biopharma and medtech companies' clinical-stage R&D programmes.